Cross-Database Mapping of PCSK9 Inhibitor Research: A Bibliometric Analysis of Scopus and PubMed

Introduction Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are transformative lipid-lowering therapies, yet the structure of the research literature is strongly shaped by trial priorities. This study aimed to map global research trends on PCSK9 inhibitors using a bibliometric analysis of Scopus and PubMed. Methods Metadata on publication year, journal, citations, authorship, country, institution, and keywords were extracted. Annual output, mean citations, h-index correlations, and collaboration metrics were calculated, and networks were visualized using Bibliometrix and VOSviewer. Results Approximately 1,390 records published between 1994 and 2024 were identified, involving 7,601 authors and 51,555 citations, with a mean of 37.1 citations per document. Network mapping revealed eight collaboration clusters and an international collaboration index of 1.871. The United States contributed the largest share of corresponding-author articles, with 343 of 1,390 records (24.7%), while the top 10 countries accounted for approximately 65% of outputs. Publication volume increased sharply after 2013, with inclisiran emerging as a highly cited RNA-based therapeutic. However, annual publication volume was not significantly correlated with mean citations (r = 0.059, P = 0.832), indicating no proportional increase in per-article citation influence. Discussion Network analysis identified eight major collaboration clusters. International collaboration was modest, with limited contributions from low- and middle-income countries. Temporal trends showed a notable increase in publications after 2013. Emerging RNA therapeutics were visible in the dataset but had lower citation maturity compared with established monoclonal antibody studies. Conclusion Scopus and PubMed mapping reconstructs the translational progression of PCSK9 research and highlights collaboration patterns, country-level contributions, and the bibliometric visibility of emerging therapeutic modalities.